The cobas h 232 system is an instrument for the quantitative evaluation of immunoassays (NT-proBNP, troponin T, D-dimer and myoglobin) that allows a fast and precise cardiovascular diagnosis.
Reliability
Patient management efficiency
Ease of use
Rapid results
Potential cost savings
Enhanced workflows
The cobas h 232 system:
is a state-of-the-art, self-contained and easy-to-use portable device;
gives cardiac test results within fifteen minutes;
provides results comparable to Roche laboratory methods;
delivers state-of-the-art quality assurance features such as patient identification and quality control lock-out;
features automatic calibration and is maintenance-free;
only requires 150 µl heparinized whole blood;
maximizes its capabilities when connected to the comprehensive cobas IT 1000 data management solution ensuring PoC management and results quality from the main laboratory.
Diagnosis and assessment of congestive heart failure
Risk stratification in acute coronary syndrome
Result after 12 minutes, 60-9000 pg/ml range
Diagnosis of acute coronary syndrome and myocardial infarction
Result after 12 minutes, 0.1–2.0 ng/ml range
Exclusion of deep-vein thrombosis and pulmonary embolism
Result after 8 minutes, 0.1–4.0 µg/ml range
Early marker of myocardial damage to assist in diagnosis of acute coronary syndrome and myocardial infarction
Result after 8 minutes, 30–700 ng/ml range
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.
You are now leaving the website of Hoffmann-La Roche Ltd. ("Roche Canada"). Links to all external sites are provided as a resource to our visitors. Roche Canada assumes no responsibility for the content of these sites. Roche Canada has no control over these sites and the opinions, claims or comments contained in these sites should not be attributed to Roche Canada, unless otherwise specified.